Aryl Aldonamides Inhibit Ice Recrystallization in Cryopreserved Stem Cells
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cryopreservation methods for biological materials, such as stem cells and umbilical cord blood, face challenges due to cellular damage from ice recrystallization during thawing, with existing cryoprotectants like DMSO being cytotoxic and lacking effective alternatives that can inhibit ice recrystallization effectively.
Innovation Solution
Development of small molecule ice recrystallization inhibitors, specifically mono- or di-substituted aryl aldonamides, which alter the structure of bulk water to inhibit ice recrystallization, are used in cryopreservation compositions and methods, including fractionating umbilical cord blood and mixing hematopoietic stem cells with these inhibitors before freezing.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DMSO is used as a cryoprotectant, then cell viability is improved, but cytotoxicity increases
Solution Approach 1:
The patent changes the chemical parameters of the cryoprotectant by using small molecule ice recrystallization inhibitors (such as mono- and di-substituted aryl aldonamides) instead of traditional cryoprotectants like DMSO. These small molecules have different chemical properties that allow them to inhibit ice recrystallization without causing the cytotoxic effects associated with DMSO, thereby maintaining cell viability while reducing harmful effects.
Solution Approach 2:
The patent employs small molecule inhibitors that can be easily introduced and removed from the cryopreservation system. These small molecule aryl aldonamides serve as temporary protective agents during the freezing and thawing process, providing protection without the long-term cytotoxic concerns of traditional cryoprotectants, and can be readily discarded or diluted after use.
2Reliability
If conventional cryoprotectants are used, then ice recrystallization is inhibited, but cellular damage occurs
Solution Approach 1:
The patent extracts the essential function of ice recrystallization inhibition from traditional cryoprotectant formulations and achieves it through specific small molecule inhibitors. By isolating and using only the active small molecule components (aryl aldonamides) rather than complex cryoprotectant mixtures, the patent maintains ice recrystallization inhibition while eliminating the harmful cellular damage effects of conventional formulations.
Solution Approach 2:
The patent fundamentally changes the molecular parameters of the ice recrystallization inhibitor by using small molecule aryl aldonamides instead of large molecule cryoprotectants. This parameter change allows the inhibitor to bind to ice crystals and prevent recrystallization through different mechanisms that do not cause cellular damage, thereby resolving the contradiction between inhibition effectiveness and cellular harm.
3Object-generated harmful factors
If alternative cryoprotectants to DMSO are used, then cytotoxicity is reduced, but ice recrystallization inhibition effectiveness decreases
Solution Approach 1:
The patent changes the molecular size and chemical structure parameters by introducing small molecule aryl aldonamides as cryoprotectants. These small molecules have optimized structures that enable effective ice recrystallization inhibition through direct interaction with ice crystal surfaces, achieving both low cytotoxicity and high inhibition effectiveness simultaneously, thus resolving the trade-off between safety and effectiveness.
Solution Approach 2:
The patent creates a composite cryopreservation system by combining small molecule ice recrystallization inhibitors with standard cryopreservation protocols and supporting media. This composite approach allows the small molecule inhibitors to work synergistically with existing cryopreservation methods, achieving effective ice recrystallization inhibition without the cytotoxicity of traditional cryoprotectants while maintaining compatibility with standard laboratory procedures.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These inhibitors significantly improve cell viability and functionality post-thaw, offering a viable alternative to DMSO by effectively inhibiting ice recrystallization and maintaining high cell viability and functionality during cryopreservation.
Implementation Method 1
small molecule ice recrystallization inhibitors, specifically mono- or di-substituted aryl aldonamides, which alter the structure of bulk water to inhibit ice recrystallization
Data Source
AI summary
Ice recrystallization inhibitor (IRI) compounds and methods for cryopreserving umbilical cord blood are provided. The compounds are unsubstituted, mono-substituted, or di-substituted aryl-aldonamides. The methods include fractionating whole umbilical cord blood to generate a fraction comprising hematopoietic stem cells, mixing the hematopoietic stem cells with at least one IRI compound to form an IRI suspension, and freezing the IRI suspension.